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Abstract: The atypical antipsychotic sertindole is a phenylindole-derived compound that has 
affinity for and functions as an antagonist at a number of receptor systems, including dopamine 
D2 receptors, 5-HT2A and 5-HT2C receptors, and α-1-noradrenergic receptors. Although previous 
data suggested that sertindole was well tolerated and had good efficacy against both positive and 
negative symptom clusters, reports of QT prolongation with sertindole prompted its voluntary 
removal from the market in 1998. After further safety analyses, it recently regained approval 
and was reintroduced to the European market for the treatment of schizophrenia, where its 
role in therapy among available atypicals remains unclear. This article evaluates the preclinical 
and clinical data regarding sertindole’s effectiveness and concludes that sertindole continues 
to demonstrate a number of strengths, including effective management of both positive and 
negative symptoms, well-tolerated side effects (including little or no sedation, weight gain, and 
extrapyramidal side effects), and a superior procognitive profile that is unique among atypical 
antipsychotics. However, minor concerns regarding its sexual side effects and the major consid-
eration of QT prolongation suggest that additional comparative effectiveness studies are needed 
to determine the superiority of sertindole vs other atypical antipsychotics recently introduced.
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Introduction to management issues  
in the treatment of schizophrenia
Over the past 60 years, the environment surrounding the treatment of   schizophrenia 
has changed dramatically. Historically, the treatment of the disease was managed in 
  psychiatric institutions, where individuals were confined for much, if not all, of their lives. 
Following the introduction of the first antipsychotic medications (eg,   chlorpromazine, 
haloperidol), however, treatment paradigms began to evolve from longer-term, in-patient 
treatment toward a system of managed outpatient care that is the current model of treat-
ment regimens. At present, traditional and atypical   antipsychotics remain the primary 
avenue of treatment for the disease and have demonstrated effectiveness in treating 
the presentation of both acute psychotic breaks and preventing relapse.1–3 Moreover, 
atypical antipsychotics have the additional benefit of demonstrating remarkable efficacy 
against the negative symptom cluster of schizophrenia.4
However, it is clear that many problems still exist in terms of unmet needs in the 
pharmacological treatment of schizophrenia. First, there continues to be a large num-
ber of patients who demonstrate a poor response to treatment with antipsychotics.5,6 
A second issue associated with the use of these agents is their undesirable side-
effect profiles that may impair both quality of life (eg, sedation, lethargy, sexual Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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dysfunction) and physical health (eg, weight gain, obesity, 
hypertension).7 A third arena of concern is the not infrequent 
development of extrapyramidal side effects (EPS), such 
as dystonia,   Parkinsonism, and tardive dyskinesia, which 
occur more commonly after chronic treatment with tradi-
tional   antipsychotic medications. In fact, tardive dyskinesia 
occurs in about one-fifth of patients with schizophrenia who 
are prescribed chronic regimens of first-generation agents8 
and is often associated with social stigmatization. Thus, the 
well-established, problematic side-effect profiles of both tra-
ditional and atypical antipsychotics make balancing the treat-
ment of the disease against other negative health concerns, 
such as sedation, weight gain,9,10 metabolic disorders,11,12 and 
prolactin elevation,13,14 challenging at best.
Recently, it has become evident that the long-term 
treatment of schizophrenia is compounded by significant 
impairment in cognitive domains. Although this would 
seem to be a more recent observation, even Kraepelin’s 
initial characterization of schizophrenia from over a cen-
tury ago included descriptions of cognitive deficits,15 and 
these   perspectives have gained greater attention in the more 
recent treatment literature.16,17 Cognitive deficits observed 
in patients with schizophrenia appear widespread and are 
related to executive function, working memory, and attention. 
These cognitive deficits are present at the onset of illness, 
persist for most of patients’ lives without remission, and may 
precede the development of positive symptoms.18,19 Unlike 
psychotic symptoms, cognitive deficits demonstrate a robust 
inverse association with community functioning and illness 
outcome.20–22 Therefore, treatments that attenuate cognitive 
deficits have the potential to significantly improve patients’ 
quality of life.
Conventional antipsychotic treatments (eg, haloperidol) 
are reported not only to lack effect on cognitive deficits23 
but also to impair some cognitive functions.24,25 Novel 
antipsychotic compounds (second-generation or “  atypical” 
antipsychotics), such as clozapine,26 olanzapine,27 and 
sertindole,28,29 have demonstrated some beneficial effects on 
negative symptoms and reduced potential to produce EPS, 
but these agents have demonstrated inconsistent effects on 
cognitive function in patients with schizophrenia. Depending 
on the type of cognitive domain measured, second-generation 
atypical antipsychotics have been reported to produce 
improvement,23,30,31 no effect,30,32 and impairment.33 Thus, 
finding effective treatments that manage both positive and 
negative symptoms while also having the capacity to address 
cognitive dysfunction would seem to be the key.
A final aspect for consideration in the management of 
schizophrenia is the total costs incurred due to disease. 
Certainly, schizophrenia places a heavy burden on society 
because of the large demand on the health care infrastructure 
but just as important is the burden placed on families and 
caretakers. Schizophrenia, long considered the most chronic, 
debilitating, and costly mental illness, now consumes a total 
of about US$63 billion a year for direct treatment, societal, 
and family costs.34 Schizophrenia accounts for a fourth of all 
mental health costs and takes up 1 in 3 psychiatric hospital 
beds.34 To the effect that only 10%–15% of people with 
schizophrenia are able to maintain full-time employment 
of any type,34 public assistance assumes the cost of living. 
In 2002, the total direct nonhealth care excess costs in the 
United States, including living cost offsets, were estimated 
to be US$7.6 billion with indirect excess costs (primarily due 
to un- and under-employment) of US$32.4 billion.34 Thus, 
schizophrenia is a debilitating illness resulting in significant 
costs that must be considered in a discussion of emerging 
treatments.
Risks and benefits in use  
of sertindole
Sertindole, manufactured by H Lundbeck A/S (Copenha-
gen, Denmark), is an atypical antipsychotic that has proven 
clinical efficacy in the treatment of schizophrenia psychosis 
and also improves negative symptoms without producing 
EPS, when compared with traditional antipsychotics.35,36 
Previous work has demonstrated that striatal D2 occupancy 
is a predictive measure of antipsychotic clinical efficacy37,38 
and also suggests that antipsychotic efficacy is not associ-
ated with a high degree of striatal D2 receptor occupancy in 
schizophrenia.39
After introduction of sertindole to the European market 
in 1996, concerns regarding an association with prolonged 
QT intervals, possibly related to fatal ventricular arrhythmias 
including Torsade de Pointes (TdP), led to its voluntary 
withdrawal from the market in December 1998. Because of 
these apparent risks, a number of studies were undertaken 
to investigate sudden death claims related to sertindole, yet 
none of the studies thus far have been able to confirm that 
sertindole conveys an increased risk of sudden death.40–44 As 
such, sertindole was re-released and was made available in 
the European market for prescriptions beginning in 2006 with 
the stipulation of close electrocardiogram (ECG) screening 
and monitoring. Further studies have shown that sertindole 
has a low arrhythmogenic potential and is not associated Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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with a rate of cardiovascular mortality higher than other 
antipsychotic agents.44
Pharmacology, mode of action, and 
pharmacokinetics of sertindole
Sertindole is phenylindole-derived compound that is clas-
sified as a second-generation, or atypical, antipsychotic 
medication. It has affinity for and functions as an antagonist 
at a number of receptor systems, including dopamine D2 
receptors, 5-HT2 receptors (particularly 2A and 2C sub-
types), and α-1-noradrenergic receptors.45 Antagonism of 
these receptor systems are hypothesized to be involved in the 
antipsychotic effectiveness.46 Like other atypicals, sertindole 
has selective effects on the dopaminergic system, affecting 
the mesocorticolimbic rather than mesostriatal neurons.45,47 
Previous data have implicated a number of atypical antipsy-
chotics, including risperidone, sertindole, and ziprazidone, 
in QT prolongation.48–50 An extended discussion of sertindole 
clinical pharmacokinetics is beyond the scope of this review 
(for a review of antipsychotic clinical pharmacokinetics, 
see Mauri et al51), but we will briefly address the issues of 
arrhythmias and metabolism/pharmacokinetics.
When concern was raised over the potential for sertindole 
to provoke fatal arrhythmias, the cardiac effects of sertindole 
were investigated in several preclinical and clinical studies.52–54 
Most antipsychotic agents have been demonstrated to show 
electrophysiological effects resembling those of antiarrhyth-
mic agents, and indeed may be responsible for QT-interval 
prolongation.55 Sertindole was ranked as the new atypical agent 
having the greatest risk of producing QT-  interval prolongation, 
followed by ziprasidone and risperidone (both producing mod-
erate risk) with the atypical compounds clozapine, olanzapine, 
and quetiapine deemed to have no effects on QT intervals.56 In 
healthy dogs, sertindole exposure was not associated with the 
development of TdP, but in dogs with chronic atrioventricular 
block, high intravenous doses of sertindole were able to induce 
TdP.57 The proarrhythmic effect of sertindole was subsequently 
compared with sotalol, a class III antiarrhythmic with inhibitory 
effects on potassium ion channels and β-adrenergic receptors.58 
The QTc effects of sotalol and sertindole were comparable, but 
at low potassium levels sotalol elicited TdP, whereas sertindole 
only elicited monomorphic tachycardia and nonsustained 
polymorphic tachycardia. This difference has been attributed 
to sertindole’s concurrent inhibitory effects on sodium and cal-
cium influx channels,59 as well as to its α-1-adrenoceptor block-
ade, whereby a reflex sinus tachycardia may protect against the 
development of TdP specifically. Sertindole also has a low ratio 
of myocardium/plasma distribution; thus, this limited distribu-
tion to the myocardium may decrease the effective concentration 
at rapid delayed rectifier K+ channels (IKr sites).60
Excessive weight gain is a common side effect of some, 
but not all, typical and atypical antipsychotic medications, 
with clozapine and olanzapine being the antipsychotic medi-
cations with the greatest likelihood of inducing weight gain 
(for reviews, see Baptista et al61 and Spina and de Leon62). 
Sertindole treatment engenders relatively moderate weight gain 
that is comparable to risperidone, but greater than ziprazidone, 
amisulpride, haloperidol, fluphenazine, pimozide, and molin-
done. Notably, sertindole produces less weight gain than many 
antipsychotics, including clozapine, olanzapine, quetiapine, 
zotepine, chlorpromazine, and thioridazine.61 Given the various 
mechanisms of action for sertindole, any weight gain observed 
in patients may result either from increased appetite due to drug 
interactions with cholinergic and monoaminergic systems or 
perhaps from hyperprolactinemia. In addition, one problematic 
issue with the treatment of schizophrenia is that polypharmacy 
(or drug “cocktails”) might be used in treatment regimens, and 
as such, additive weight gain effects resulting from treatment 
with multiple antipsychotics might be observed.
The introduction of the atypical antipsychotics in the treat-
ment of schizophrenia coincided with an increased awareness 
of the potential for drug–drug interactions,   particularly involv-
ing the cytochrome P450 (CYP) enzymes. When considering 
drug–drug interactions, it is useful to anchor any comparisons 
against clozapine, which is often considered the standard of 
the atypical agents. Clozapine has a rather complex phar-
macokinetic profile, with large interpatient variability and 
many drug interactions.63 In contrast, olanzapine presents as 
a medication with a very low incidence of drug interactions, 
largely as a result of requiring exceedingly high inhibition of 
CYP450 systems.64 The results of both in vivo65 and in vitro66 
experiments suggest that the metabolism of sertindole is prin-
cipally mediated by CYP3A4 and CYP2D6, and the known 
variability of these 2   isoenzymes likely contributes to the 
observed variability in the pharmacokinetics of sertindole.67 
In addition, the inhibitory potential of sertindole at CYP2A,68 
CYP2D6, and CYP3A469 is relatively modest and not likely 
to be of any clinical significance in any patients, except for 
those already taking CYP2D6 inhibitors or those who are 
poor metabolizers. In contrast, sertindole was observed to 
produce direct inhibitory effects on CYP2B68 and CYP2C6 
activities in vitro.70
Sertindole is relatively well absorbed when administered 
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Dovepress 
Dovepress
432
Cincotta and Rodefer
bound (99.5%) to plasma proteins. At doses of 4–32 mg/d, 
the Tmax is 8–12 hours and the terminal elimination half-life 
ranges from 50 to 111 hours.67 The mean elimination half-life 
of sertindole is about 70 ± 60 hours, with an oral clearance 
of 40 ± 31 L/h.71 The mean Cmax of sertindole was 2 ng/mL 
after the first dose and 10 ng/mL after the seventh dose.72 
Given these data, it is not surprising that significant sertindole 
accumulation can occur during multiple dosing. Dosing with 
12 mg/d and 20 mg/d can produce steady-state levels after 
about 9 and 5 days, respectively.71
Sertindole is metabolized into major (Lu 30-131, 
5-hydroxy-sertindole; Lu 30-148, 4-hydroxy-sertindole) and 
minor (Lu-25-073, norsertindole; Lu 28-092 dehydrosertin-
dole; Lu 30-131, 5-hydroxy-sertindole) metabolites,73 and 
none of these metabolites are reported to demonstrate any 
therapeutic effect. Moreover, sertindole pharmacokinetics 
do not seem to be significantly affected by age, sex, or race/
ethnicity.74 Because of metabolism pathway considerations, 
concurrent administration of CYP inhibitors, such as fluox-
etine or paroxetine, is cautioned as these will likely increase 
plasma sertindole concentrations, whereas CYP inducers, 
such as carbamazepine or phenytoin, will decrease them. 
Additional care is needed when calculating effective doses in 
patients with hepatic insufficiency. The pharmacokinetics of 
sertindole are unchanged by renal impairment and deficiency, 
thus no dose adjustment is necessary in subjects diagnosed 
with renal insufficiency or in subjects with renal failure 
requiring dialysis treatment.73 The main excretion pathway 
for sertindole is via feces and is observed across species.65
Efficacy
The therapeutic efficacy of sertindole in patients with 
  schizophrenia has been evaluated in 1 flexible-dose direct com-
parison with placebo, 3 efficacy comparisons with   haloperidol, 
and 2 randomized controlled trials (RCTs) vs risperidone (see 
Table 1). Smaller retrospective and observational reports are 
available and will only briefly be noted here.
In a placebo-controlled, dose-ranging study of sertindole 
(8, 12, and 20 mg/d) in 153 patients with schizophrenia, 
use of sertindole 20 mg/d was associated with significantly 
greater improvements from baseline in the Clinical Global 
Impression (CGI) scale as well as in the Positive and   Negative 
Syndrome Scale (PANSS) and Brief Psychiatric Rating 
Scale (BPRS) total scores, relative to placebo after 40 days.36 
Although the 8-mg/d dose was associated with numerically 
greater reductions on the PANSS and BPRS total scores, 
the difference was not significant. This study, therefore, 
  suggested a dose-response relationship between sertindole 
and improvement in psychiatric rating scales and established 
20 mg/d as an effective, well-tolerated dose.
Data from 3 randomized trials suggest that sertindole 
is at least as effective as haloperidol in the treatment of 
schizophrenia and may be more effective in treating negative 
symptoms specifically. In a double-blind, placebo-controlled, 
dose-ranging trial of sertindole (12, 20, and 24 mg/d) and 
haloperidol (4, 8, and 16 mg/d) in 497 hospitalized patients 
with schizophrenia, both sertindole and haloperidol were 
associated with significantly greater improvements at all 
doses on PANSS and BPRS total scores compared with 
placebo.75 A significant reduction was also noted in the CGI 
scale relative to placebo with all doses of sertindole and all but 
the 4-mg/d dose of haloperidol. All doses of haloperidol and 
only the 20- and 24-mg/d doses of sertindole were associ-
ated with significant reductions in the   positive syndrome 
subscale of the PANSS. Interestingly, only the 20-mg/d 
dose of sertindole was significantly superior to placebo in 
improving negative symptoms as measured on the PANSS 
subscale and Scale for the Assessment of Negative Symp-
toms (SANS) over the course of the study. In a longer-term, 
randomized study of sertindole (24 mg/d) vs haloperidol 
(10 mg/d) in 282 outpatients with schizophrenia, sertindole 
was associated with a significantly greater reduction in the 
SANS total score from baseline after 2 months of treatment; 
however, there was no significant difference between the 
2 treatment groups after 12 months.76 In another double-
blind, randomized, dose-ranging study of sertindole (8, 16, 
20, and 24 mg/d) vs haloperidol (10 mg/d) in 617 patients 
with schizophrenia, sertindole (16 mg/d) demonstrated sig-
nificantly greater improvement on the negative subscale of 
the PANSS compared with haloperidol (10 mg/d).77 Increas-
ing the dose of sertindole to 20–24 mg/d revealed no greater 
benefit in terms of either PANSS total or negative subscale 
scores. There were no significant differences between sertin-
dole (16–24 mg/d) and haloperidol (10 mg/d) on PANSS 
total score improvement.
Direct comparisons of sertindole with second-generation 
antipsychotic drugs are lacking and are currently limited 
to two 12-week RCTs with risperidone, and these analyses 
are limited themselves by early study termination upon 
  withdrawal of the drug from the market. A randomized, 
double-blind study initially revealed superior efficacy of 
sertindole (12–24 mg/d) over risperidone (4–10 mg/d) on 
both PANSS total and negative symptom subscale scores in 
186 patients with schizophrenia.29 A subsequent randomized, 
double-blind study comparing sertindole (12–24 mg/d) with 
risperidone (6–12 mg/d) in 217 treatment-resistant (defined as Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Table 1 Efficacy studies of SER vs PL, HAL, and RIS
Reference Treatment  
length (wk)
Drug and  
dose (mg/d)
No. (ITT 
analysis)
Efficacy measure (mean decrease from baseline to final 
assessment)
PANSS  
total
PANSS 
positive
PANSS 
negative
BPRS CGIa SANS
vs placebo
van Kammen et al36 6–7 SeR 8 35 5.0 1.6 0.2 4.4 4.0
SeR 12 40 12.1 3.0 2.1 8.0 3.5
SeR 20 40 16.9* 3.5 3.0 10.4* 2.9*
PL 38 5.8 1.6 1.3 4.8 3.8
vs haloperidol
Zimbroff et al75 8 SeR 12 72 10.0b** 2.4 2.5b 6.7** 3.5** 7.9*
SeR 20 65 17.6b*** 4.8*** 4.3b*** 10.3*** 3.3** 13.2***
SeR 24 70 10.8b** 3.2* 2.2b 8.2** 3.6** 7.1
HAL 4 68 11.8b** 2.7* 2.5b 8.0** 3.7 10.9
HAL 8 63 16.5b*** 5.6*** 3.3b 10.4*** 3.1*** 10.8
HAL 16 68 12.2b** 4.3*** 2.2b 8.8** 3.5* 7.1
PL 71 -0.8b 0.0 0.7b 0.9 4.2 2.1
Daniel et al76 52 SeR 24 94 5.8 3.9
HAL 10 109 1.4 0.1
Hale et al77 8 SeR 8 116 16.2 4.6 4.2 3.1
SeR 16 120 23.8† 6.9† 5.7 3.0
SeR 20 121 20.1 6.3 4.9 3.1
SeR 24 115 23.1† 7.6† 4.8 3.0
HAL 10 123 22.8† 7.9† 4.3 3.0
vs risperidone
Azorin et al29 12 SeR 12–24 90 29.3 8.0 7.7‡ 1.4c
RiS 4–10 82 25.8 7.2 6.4 1.3c
Kane et al78 12 SeR 12–24 213 12.0 3.3 2.5 7.0 0.5c 7.5
RiS 6–12 102 19.0 5.8 3.7 10.9 0.8c 10.3
Notes: aCGI value is mean actual score on CGI improvement scale at final assessment (1, very much improved; 4, no improvement; 7, very much worse).
bValues estimated from a graph; as estimated by Murdoch and Keating.84
cMean decrease on CGI-S (severity scale) from baseline to final assessment.
*P , 0.05; **P , 0.01; ***P , 0.001 vs placebo, †P # 0.05 vs SeR 8 mg/d; ‡P # 0.05 vs RiS 6–12 mg/d.
Abbreviations: SER, sertindole; PL, placebo; HAL, haloperidol; RIS, risperidone; ITT, intention to treat; PANSS, positive and negative syndrome scale; BPRS, brief psychiatric 
rating scale; CGi, clinical global impression; SANS, scale for the assessment of negative symptoms.
failure of adequate trials of $2 antipsychotic agents) patients 
with schizophrenia, however, demonstrated no significant dif-
ferences in the same efficacy measures from baseline to final 
assessment.78 A recent Cochrane review of pooled RCT data 
similarly revealed no difference in efficacy between these 2 
antipsychotic drugs.79 Sertindole, therefore, appears at least 
as effective as high-dose risperidone, however, its efficacy 
vs other atypical agents remains unclear.
Two small observational studies have reported   significant 
improvement from baseline in patients treated with   sertindole. 
In a naturalistic study of 53 patients with   psychotic disorders 
prescribed sertindole (8–24 mg/d) before its withdrawal from 
the market, improvement in global assessment of functioning 
(GAF) and CGI scores between admission and discharge was 
highly significant (P , 0.001).80 Another smaller observa-
tional study of 34 patients with   psychotic disorders reported an 
85% response rate (defined as achieving a CGI score # 3) with 
sertindole use initiated in the inpatient setting.42 In summary, 
both real-world and clinical research data support the efficacy 
of sertindole in the treatment of patients with schizophrenia 
(and to a lesser extent other psychotic disorders), although 
current evidence for its efficacy is limited to comparisons 
with placebo, haloperidol, and risperidone.
Safety and tolerability
QT prolongation
The association between sertindole use and QT prolongation 
has been demonstrated since its introduction to the European 
market, when clinical trials first documented a 20-millisecond 
heart rate corrected QT interval increase with sertindole use.81 
Shortly thereafter, the proportion of fatal cardiac arrhythmias 
and sudden deaths associated with sertindole (7.5%) were 
found to outnumber almost 10-fold those of either risperi-
done (0.8%) or olanzapine (0.9%) on the Adverse Drug 
  Reactions Online Information Tracking (ADROIT) database, 
a   regulatory monitoring system in the United Kingdom for Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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physician reports of adverse drug reactions.40 These data 
prompted the manufacturer, Lundbeck Pharmaceuticals, to 
withdraw sertindole voluntarily from the market and conduct 
further studies to confirm the ADROIT data. Five subsequent 
epidemiological studies taken together established that sertin-
dole was associated with no greater risk of death or serious 
cardiac adverse drug reaction than other second-generation 
antipsychotic drugs;40,43,44,82,83 however, adverse drug reac-
tions associated with sertindole were determined to be more 
frequently reported than those of other atypical agents.41
In 2002, the European Committee for Proprietary 
Medicinal Products decided to reintroduce sertindole to the 
  European market with the stipulation that all sertindole-
treated patients were to be included in a postmarketing 
surveillance study.84 Data from that cohort, the Sertindole 
Cohort Prospective (SCoP) study, failed to determine any 
overall difference in all-cause mortality rates compared 
with treatment with risperidone; however, significantly more 
patients treated with sertindole died from an event considered 
possibly cardiac (ie, there was no evidence of a noncardiac 
cause) than those given risperidone.85 Another study con-
ducted under the named patient use program after sertindole’s 
suspension, the Sertindole Safety Survey, retrospectively 
analyzed the serious adverse events (SAEs) reported among 
1,432 patients treated with sertindole in 11 European coun-
tries.86 Of the 97 SAEs identified, 10 had fatal outcomes 
(2 suicides, 3 sudden deaths [2 myocardial infarctions and 1 
pulmonary embolism], 4 “other” deaths, and 1 unascertained 
cause of death). Of the 87 remaining nonfatal SAEs, 24 were 
considered cardiac in origin (15 cases of QT prolongation, 
4 heart rate anomalies, 3 cardiac failures, 1 abnormal ECG, 
and 1 myocardial infarction).
The association between sertindole and QT prolongation 
remains robust, with industry-sponsored retrospective analysis 
replicating the increase of 20 ± 26 millisecond in sertindole-
treated patients (n = 160) vs a decrease of 5 ± 22 millisecond 
among controls (n = 162) (from Lundbeck data).87 A smaller, 
noncontrolled trial of 21 patients with schizophrenia treated with 
an average dose of 14.7 ± 4.6 mg/d of sertindole found a signifi-
cant increase in mean QTc interval from 387.7 ± 19.2 millisec-
ond at baseline to 402.8 ± 23.8 millisecond after 6 months.88 Of 
course, sertindole is not unique amongst its class in its propen-
sity to prolong the QTc interval; olanzapine (1.7 millisecond at 
20 mg/d), risperidone (3.6 millisecond at 16 mg/d), quetiapine 
(5.7 millisecond at 750 mg/d), and ziprasidone (15.9 millisecond 
at 160 mg/d) have all been documented to lengthen the QTc 
interval, albeit not more than the first-generation neuroleptic 
thioridazine (30.1   millisecond at 300 mg/d).89 Independent of its 
association with QT prolongation,90,91 however, sertindole has 
also been shown to induce T wave morphologic changes (flat-
ness, asymmetry, or notches) in a majority (26 of 37 patients) 
of patients in one study, suggesting that patients predisposed 
to arrhythmias or even sudden cardiac death may be missed 
if patients are only screened for QT prolongation.92 In sum-
mary, sertindole is associated with a prolongation of the QT 
interval that has not been linked to the development of cardiac 
arrhythmias, however, further evidence will be helpful in elu-
cidating the impact, if any, of its electrophysiological profile 
on cardiac-related mortality.
extrapyramidal symptoms
The reduced incidence of EPS associated with second-
  generation antipsychotic drugs has been attributed to their 
limbic preferentiality and decreased striatal dopamine D2 
receptor occupancy relative to their typical counterparts. 
In following, available data suggest that sertindole may be 
associated with a lower incidence of EPS compared with halo-
peridol and risperidone. In a double-blind, controlled study 
of sertindole vs risperidone, patients treated with sertindole 
(at a mean dose of 16.2 mg/d) experienced numerically fewer 
EPS-related treatment-emergent adverse events than those 
given risperidone (6.6 mg/d; 19% vs 28%).29 More recently, 
another double-blind, randomized study   comparing sertindole 
(12–24 mg/d) with risperidone (6–12 mg/d) revealed a sig-
nificantly lower incidence of EPS among sertindole-treated 
patients (20.8% vs 36.2%, P , 0.01).78 Unsurprisingly, 
sertindole (24 mg/d) has been associated with a significantly 
lower incidence of EPS-related adverse events relative to 
haloperidol (4–16 mg/d) after 8 weeks of treatment (23.6% 
vs 43.7%–55.7%), with rates   indistinguishable from placebo 
(27.4%).75 A long-term efficacy trial of sertindole similarly 
revealed a 17% lower incidence of EPS associated with 
sertindole (24 mg/d) compared with haloperidol (10 mg/d).76 
Importantly, the emergence of EPS with sertindole use does 
not appear to be dose-dependent,36 whereas the incidence 
of EPS with olanzapine and risperidone has been found to 
increase with higher doses.54
Although the incidence of EPS with sertindole may 
appear exceptionally low, there is currently no data compar-
ing the risk of EPS between sertindole and other atypical 
antipsychotics with lower dopamine D2 receptor affinity 
than risperidone. In conjunction with its low risk of EPS, 
however, sertindole may have a role in treating patients with 
  undesirable movement disorders associated with the use of 
conventional neuroleptics. In one case series of 4 patients with 
tardive dystonia, dyskinesia, or akathisia, switching from a Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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first-generation antipsychotic drug to sertindole considerably 
improved both the movement disorder and the severity of 
psychotic symptoms,93 although this effect has been noted 
with olanzapine, quetiapine, and clozapine as well.94
Metabolic profile and weight
The prevalence of metabolic syndrome among patients with 
schizophrenia now doubles that of the general population, 
conferring tremendous risk of diabetes and heart disease most 
notably to those treated with second-generation antipsychotic 
drugs.95 Limiting the risk of metabolic syndrome has accord-
ingly become a priority within both clinical   practice and drug 
development. In a subset of 261 patients with schizophrenia 
randomized to receive either sertindole or risperidone, neither 
treatment was associated with an increased risk of metabolic 
syndrome from baseline to last assessment, spanning up 
to 12 months.96 However, both sertindole and risperidone 
use were associated with an increase in weight (1.8 and 
1.7 kg, respectively), waist circumference (1.4 and 1.5 cm, 
respectively), and body mass index (0.6 and 0.6 kg/m2, 
respectively). Placebo-controlled trials have noted similar, 
small but significant weight increases with sertindole vs 
placebo use, with weight gain ranging from 2.2 to 3.3 kg 
over 40–56 days of treatment.36,75 Double-blind trials of 
sertindole vs risperidone also reported a 2.1- to 3.1-kg weight 
gain with sertindole, which did not differ significantly from 
that of risperidone (1.5–2.5 kg) over 12 weeks.29,78 Treat-
ment with sertindole has also been associated with small 
increases in plasma glucose,78,96 total cholesterol,36,78 and 
triglycerides,78 although most studies report negative results 
on these parameters.
Other treatment-emergent  
adverse events
Both placebo-controlled and randomized, controlled compara-
tor trials with sertindole suggest that it is well tolerated among 
patients with schizophrenia. Adverse event reporting from 
6 trials (see Table 2) suggests that sertindole is most commonly 
associated with rhinitis/nasal congestion (15.3%–34.7%), 
nausea (11.0%–13.0%), abnormal ejaculation (8.9%–21.8%), 
insomnia (9.3%–31.3%), somnolence (8.2%–18.1%), and 
headache (5.2%–33.8%). Interestingly, the only adverse event 
reported in all 6 trials was abnormal ejaculation, including both 
decreased ejaculatory volume and absence of ejaculation. The 
ejaculatory abnormalities associated with sertindole use may 
stem from its α-1-adrenoreceptor antagonist activity,35 which 
has been linked to ejaculatory dysfunction with risperidone97 
and thioridazine98 use, although this remains speculative. 
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  Overall, however, rates of withdrawal from trials of sertindole 
were low, ranging from 0.4% to 12.2% within the 6 trials 
included in Table 2. Limited naturalistic data also indicate 
that sertindole is well tolerated relative to other antipsychotic 
agents. In an observational study of 53 outpatients with 
  psychotic illness who had switched from either a conventional 
or atypical neuroleptic to sertindole, clinicians rated the side-
effect profile of sertindole as better (71%), comparable (18%), 
and worse (7%) than the previous medication.80
Cognition
Cognitive dysfunction in schizophrenia remains one of the 
most devastating, functionally impairing aspects of the illness 
and as such has been an important target of antipsychotic 
drug development recently. The impact of second-generation 
antipsychotics on cognitive impairment is quite variable 
insofar as these agents have been found both to improve and 
to impair it further. One of the most well-studied paradigms 
to examine the effect of antipsychotic drugs on cognition 
is the water maze test, which depends on the function of 
working memory, learning, and attention. Two preclinical 
studies have demonstrated that sertindole, administered 
both acutely and as a 3-week pretreatment, did not impair 
performance in the water maze test, whereas both clozapine 
and olanzapine were noted to impair performance.99,100 In 
another water maze task, sertindole was similarly found to 
reverse phencyclidine (PCP)-induced deficits in learning and 
memory 1 day earlier than clozapine or risperidone.101 Sertin-
dole furthermore reversed PCP-induced deficits in a measure 
of cognitive flexibility similar to modafinil102 but unlike 
both haloperidol and second-generation agents, including 
clozapine, risperidone, and olanzapine.103 Importantly, this 
PCP-induced deficit in cognitive flexibility was also reversed 
by a 5-HT6 antagonist while a selective 5-HT2A receptor 
antagonist was without effect, highlighting a receptor profile 
factor that distinguishes sertindole from risperidone. Indeed, 
other reports from the preclinical literature have identified 
5-HT6 mechanisms as being a novel target for cognition 
impairments associated with schizophrenia and other neu-
ropsychiatric disorders.104–107 Limited data from preclinical 
reports, therefore, suggest that sertindole may improve cogni-
tive deficits in schizophrenia. Moreover, this improvement 
may be related to its unique absence of antimuscarinic and 
histamine H1 antagonist activity or to its 5-HT6 antagonist 
activity, illuminating new avenues for receptor targeting in 
antipsychotic development.
Recently, several clinical studies have explored the 
potential for sertindole to ameliorate cognitive deficits in 
patients with schizophrenia. In a randomized, double-blind 
trial comparing the effects of sertindole with haloperidol 
on cognitive dysfunction in 34 patients with schizophrenia, 
sertindole improved both reaction time and attentional 
  set-shifting significantly more than haloperidol (which 
notably worsened reaction time) at 4 and 12 weeks, 
respectively.108 In a fludeoxyglucose (FDG) PET study 
examining prefrontal cortical (PFC) activation in patients 
with schizophrenia treated with sertindole, relative glucose 
metabolic rate of the dorsolateral PFC in sertindole-treated 
patients, compared with untreated patients and haloperidol-
treated patients, was found to approach the metabolic rate 
of normal controls.109 The ability of sertindole to improve 
cognitive impairment in schizophrenia may accordingly 
relate to its selectivity for cortical and limbic structures, 
where 5-HT6 receptor antagonism has been associated with 
dopamine release and cognitive enhancement in preclinical 
models.105,110
Suicide
Suicide remains one of the leading causes of death among 
patients with schizophrenia, affecting 9%–13% of this 
population.111 Evidence that clozapine (vs olanzapine) may 
improve suicide rates has prompted further research into 
elucidating the differential impact of atypical antipsychot-
ics on this phenomenon.112 A subanalysis of the SCoP study 
following 4,905 patients treated with sertindole (12 mg/d) 
and 4,904 patients treated with risperidone (4 mg/d) for up 
to 63.5 months revealed a significantly lower incidence of 
suicide attempts (P = 0.037; fatal plus nonfatal) among those 
treated with sertindole.113 This difference in suicide rates was 
most pronounced during the first year of treatment, when 
more than 80% of the suicide attempts occurred (P = 0.0058). 
Although there were fewer completed suicides among patients 
treated with sertindole than with risperidone (0.14 vs 0.26 per 
100 patient years of exposure; PYE), the difference was not 
significant. Although limited to one study, these data suggest a 
decreased risk of suicide with sertindole vs risperidone among 
patients with schizophrenia, including those with previous 
attempts, and support future comparisons in this regard with 
other atypical antipsychotic drugs.
Patient perspectives: quality of life
Schizophrenia is a devastating illness that compromises 
familial, social, and occupational aspects of patients’ lives 
from an early age. Moreover, individual responses to treat-
ment with antipsychotic medications are highly variable 
and may further detract from a patient’s quality of life if Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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symptoms are not adequately treated or if side effects are 
intolerable. Insofar as nonadherence predicts negative treat-
ment outcomes,114 significant attention is paid to the effects 
of antipsychotic medications on quality of life and treatment 
adherence. In this regard, a retrospective study of sertindole 
use after discontinuing treatment with another antipsychotic 
agent due to either lack of efficacy or adverse events sup-
ports improved quality of life with sertindole treatment.115 
The patients were followed as they discontinued 2 antipsy-
chotic agents (periods 1 and 3, the latter lasting 7.1 months) 
to undergo treatment with sertindole 2 times over (periods 
2 and 4; 8.7 and 6.4 months in duration, respectively). The 
average number of hospitalizations arising from worsening 
symptoms decreased significantly upon first switching to 
sertindole (from 3.4 to 1 hospitalization), as did the number 
of self-harm attempts (from 22.8% to 3.5%). Notably, the 
number of patients engaged in a stable relationship increased 
significantly during both periods of sertindole treatment 
(from 38.6% to 54.4% and then from 45.6% to 57.1%), 
while the number of patients employed more than doubled 
after switching to sertindole for the first time (from 14.0% to 
31.6%). These findings suggest that patients may experience 
improvement in symptoms, as well as in social and occupa-
tional functioning, with sertindole use after discontinuing 
another antipsychotic agent that was either ineffective or 
associated with intolerable side effects.
In a year-long, double-blind trial of sertindole (24 mg/d) 
vs haloperidol (10 mg/d), sertindole use was similarly asso-
ciated with an improvement in quality of life from baseline 
as measured by the Heinrichs Quality of Life Scale (a semi-
structured interview), whereas a slight decrease in quality 
of life was noted for patients treated with haloperidol.76 In 
the same study, the time to psychotic decompensation and 
subsequent hospitalization due to patient nonadherence was 
significantly longer in the sertindole group than in the halo-
peridol group; to this effect, fewer sertindole-treated patients 
were hospitalized (2 vs 12) or withdrawn from the study 
prematurely secondary to nonadherence (2 vs 13) than those 
treated with haloperidol. A case series additionally describes 
improvements in emotional reactivity, initiative, and interest 
in 1 patient switching from risperidone (on which she had 
otherwise done well) and an improvement in positive and 
negative symptoms, weight loss, and increased compliance 
in another patient switching from olanzapine.116 On the basis 
of these reports, sertindole may represent a potential thera-
peutic alternative to improve quality of life among patients 
with persistent side effects and/or suboptimal efficacy on an 
alternative antipsychotic agent.4
Conclusions and place in therapy
With all evidence taken together, the role of sertindole in 
a treatment regimen for schizophrenia seems to be a study 
in contrasts. On the one hand, there are a number of areas 
where the treatment efficacy with sertindole is clear. First, 
those patients who are likely to benefit from sertindole 
include those who have poor control of existing positive 
and negative symptoms. Sertindole demonstrated efficacy 
advantages compared with risperidone29,115 and haloperi-
dol75 and continued to show improvement in CGI-I scores 
over a 12-month period.81 Second, sertindole seems to be 
generally well tolerated, with fewer problematic side effects 
related to sedation and weight gain. Moreover, sertindole is 
one of the few antipsychotics that demonstrates little or no 
sedation, daytime drowsiness, or increased sleep time.117 
Sertindole’s lack of effect on muscarinic and histamine H1 
  receptors118undoubtedly contributes to the lack of sedation, 
but it is also important insofar as sertindole is not associated 
with anticholinergic-mediated cognitive impairment77 or 
excessive weight gain.29,77,81 Third, sertindole treatment regi-
mens result in placebo-level EPS measures, which compares 
favorably with even the lowest doses of haloperidol (4 mg/d) 
examined,75 thus reinforcing the notion that sertindole might 
prove valuable on more severe, late-occurring movement dis-
orders.93 Fourth, and perhaps most importantly, sertindole is 
one of the few atypical antipsychotics that has demonstrated 
a reliable and robust improvement in cognitive function in 
both preclinical102,103,119 and clinical samples.35 This is per-
haps the factor that distinguishes it from most other atypical 
antipsychotics.
Another factor for consideration is that sertindole does 
display sexual side effects, producing decreased ejaculatory 
volume in more than 20% of men.35 That said, other antipsy-
chotics (eg, risperidone, thioridazine) have also been dem-
onstrated to produce sexual side effects,97,98 and the rate of 
sertindole discontinuation because of decreased ejaculatory 
volume was only 3%.35 Thus, although this effect is notable 
given the incidence rate, it does not appear to represent a bar-
rier to treatment, and it is unclear as to whether it constitutes 
a problematic side effect at a practical level.
Finally, there are 2 main considerations that may limit 
utilization of sertindole. First and foremost, sertindole is 
contraindicated for any patients with significant cardiovas-
cular disease or existing QT prolongation issues. One of 
the key requirements for the reintroduction of sertindole 
to the European market was mandatory ECG monitoring 
both before and during treatment. Thus, in a fashion similar 
to monitoring clozapine patients for the development of Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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agranulocytosis, monitoring sertindole patients may   represent 
an additional treatment burden and concern for both the 
patient and the treatment team. Moreover, these criteria 
likely disproportionately impact older patients, individuals 
with comorbid cardiovascular risk factors, and those taking 
multiple medications. Thus, the pool of patients most likely to 
benefit from sertindole may be smaller than for other atypical 
antipsychotics. Regardless, thorough screening and continued 
monitoring of sertindole patients are a necessity.
Second, there is a paucity of data comparing sertindole to 
a range of other atypical antipsychotics. Much of the literature 
to this point has drawn mostly favorable comparisons to halo-
peridol and risperidone, and although the superior efficacy vs 
haloperidol is not surprising, the favorable outcomes vs ris-
peridone are very encouraging. However, robust comparison 
with other atypicals (eg, clozapine, olanzapine, quetiapine, 
aripiprazole) is warranted. Although preclinical and clinical 
data collected to date are encouraging (eg, sertindole appears 
to have a superior efficacy profile related to cognition, weight 
gain, and PANSS), it is only with more complete comparative 
effectiveness testing vs both placebo and multiple alternative 
atypical treatment regimens120 that the true effectiveness of 
sertindole in therapy can be elucidated.
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